PROCESS FOR PREPARING THERAPEUTICALLY ADMINISTERABLE PLASMA DERIVATIVES PACKED IN READY-FOR-USE CONTAINERS

There is disclosed a method for the production of therapeutically administrable plasma derivatives filled in final containers, which are free of prekallikrein activator, hypotensively active constituents and other undesired pharmacologically active substances, of plasma or plasma crude fractions by stepwise enrichment of the plasma proteins, sterile filtration and optionally virus inactivation. In order to make available such plasma fractions that do not develop pharmacologically negative side effects when applied and are producible with an improved activity and yield, C1-esterase inhibitor is added during the production process of the plasma derivative, yet prior to its filling into final containers.